Alto Neuroscience, Inc. (ANRO)
24.98
+0.95
(+3.95%)
USD |
NYSE |
Oct 09, 13:39
Alto Neuroscience Enterprise Value : 622.87M for Oct. 8, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 08, 2026 | 622.87M |
| October 07, 2026 | 604.97M |
| October 06, 2026 | 610.94M |
| October 05, 2026 | 622.17M |
| October 02, 2026 | 649.89M |
| October 01, 2026 | 667.79M |
| September 30, 2026 | 675.51M |
| September 29, 2026 | 712.36M |
| September 28, 2026 | 715.16M |
| September 25, 2026 | 709.20M |
| September 24, 2026 | 733.41M |
| September 23, 2026 | 744.64M |
| September 22, 2026 | 859.75M |
| September 21, 2026 | 854.49M |
| September 18, 2026 | 841.85M |
| September 17, 2026 | 866.77M |
| September 16, 2026 | 832.38M |
| September 15, 2026 | 841.15M |
| September 14, 2026 | 891.34M |
| September 11, 2026 | 902.57M |
| September 10, 2026 | 891.34M |
| September 09, 2026 | 975.21M |
| September 08, 2026 | 1.036B |
| September 04, 2026 | 1.027B |
| September 03, 2026 | 1.057B |
| Date | Value |
|---|---|
| September 02, 2026 | 1.065B |
| September 01, 2026 | 1.015B |
| August 31, 2026 | 1.021B |
| August 28, 2026 | 1.012B |
| August 27, 2026 | 1.053B |
| August 26, 2026 | 1.062B |
| August 25, 2026 | 1.054B |
| August 24, 2026 | 1.052B |
| August 21, 2026 | 982.58M |
| August 20, 2026 | 981.53M |
| August 19, 2026 | 1.004B |
| August 18, 2026 | 977.32M |
| August 17, 2026 | 958.72M |
| August 14, 2026 | 907.48M |
| August 13, 2026 | 913.09M |
| August 12, 2026 | 803.60M |
| August 11, 2026 | 789.56M |
| August 10, 2026 | 772.37M |
| August 07, 2026 | 785.70M |
| August 06, 2026 | 778.68M |
| August 05, 2026 | 763.24M |
| August 04, 2026 | 770.26M |
| August 03, 2026 | 736.57M |
| July 31, 2026 | 729.55M |
| July 30, 2026 | 784.30M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ANI Pharmaceuticals, Inc. | 1.888B |
| Corcept Therapeutics, Inc. | 12.49B |
| Veru, Inc. | 18.15M |
| Johnson & Johnson | 645.94B |
| Eli Lilly & Co. | 1.147T |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -27.64M |
| Total Expenses (Quarterly) | 27.64M |
| EPS Diluted (Quarterly) | -0.6456 |
| Earnings Yield | -9.90% |
| Normalized Earnings Yield | -9.862 |